Apimeds Pharmaceuticals US Inc (APUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | |
| Cash Flows From Operating Activities | ||
| Net Income | -1,390 | -778 |
| Other Working Capital | 539 | 42 |
| Other Operating Activity | 118 | 108 |
| Operating Cash Flow | $-734 | $-628 |
| Cash Flows From Investing Activities | ||
| Investing Cash Flow | $N/A | $N/A |
| Cash Flows From Financing Activities | ||
| Debt Issued | 250 | N/A |
| Other Financing Activity | 77 | 1,032 |
| Financing Cash Flow | $327 | $1,032 |
| Beginning Cash Position | 411 | 6 |
| End Cash Position | 4 | 411 |
| Net Cash Flow | $-407 | $404 |
| Free Cash Flow | ||
| Operating Cash Flow | -734 | -628 |
| Free Cash Flow | -734 | -628 |